AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Investing.com -- AstraZeneca’s (ST: AZN) rare disease unit Alexion (NASDAQ: ALXN) said its experimental drug anselamimab ...

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.